About Monod
Monod is a company based in Seattle (United States) founded in 2021 by Alfredo Quijano Rubio and Daniel Silva Manzano. Monod has raised $25 million across 2 funding rounds from investors including HHS, Matrix Capital and Pack Ventures. Monod offers products and services including NovoBody, LuxSit™ Pro, and NovoLISA. Monod operates in a competitive market with competitors including Cardea Bio, Hememics Biotechnologies, Nix, Aligned Bio and Olaris, among others.
- Headquarter Seattle, United States
- Founders Alfredo Quijano Rubio, Daniel Silva Manzano
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Monod Bio Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25 M (USD)
in 2 rounds
-
Latest Funding Round
$290.07 K (USD), Grant
Jan 01, 2024
-
Investors
HHS
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Monod
Monod offers a comprehensive portfolio of products and services, including NovoBody, LuxSit™ Pro, and NovoLISA.
AI-powered platform for computational protein engineering in research.
Advanced system for clinical diagnostics using protein design techniques.
Software for life sciences applications in protein analysis and innovation.
People of Monod
Unlock access to complete
Unlock access to complete
Funding Insights of Monod
Monod has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $290.07 thousand completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Monod
Monod has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Matrix Capital and Pack Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pack Ventures is involved in unspecified business activities.
|
Locked | Locked | Locked | |
|
Investments in multiple sectors are made by Sahsen Ventures.
|
Locked | Locked | Locked | |
|
Early investments in science-focused startups are made by BOOM Capital.
|
Locked | Locked | Locked |
Investor details for Monod
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Monod
Investment portfolio details for Monod
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Monod
Detailed financials for Monod
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Monod Comparisons
Peer comparison for Monod
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Monod
Monod operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cardea Bio, Hememics Biotechnologies, Nix, Aligned Bio and Olaris, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital graphene biosensors are developed using machine learning.
|
|
| Locked | Locked | Locked |
Biopreservation platform for mammalian cells and biologics is developed.
|
|
| Locked | Locked | Locked |
Sweat-based biosensors are provided for body hydration monitoring.
|
|
| Locked | Locked | Locked |
Nanowire-based sensors and alignment technologies are provided for molecular detection.
|
|
| Locked | Locked | Locked |
In-vitro diagnostics are developed for oncology, transplants, and neurodegeneration.
|
Detailed competitors of Monod
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Monod
Complete news archive for Monod
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Monod
Monod was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Monod is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Daniel Silva Manzano is the current CEO of Monod. They have also founded this company.
Monod is a funded company, having raised a total of $25M across 2 funding rounds to date.
Monod was founded in 2021 and is based in Seattle, United States. Biosensors are created by the company within the biotechnology sector to identify viral proteins, toxins, antibodies, and various other molecules. The platform relies on engineered proteins combined with de novo computational protein design. Detection capabilities extend to a broad spectrum of target molecules, supporting applications in health and diagnostics.
Monod's top competitors include Nix, Olaris and Aligned Bio.
Monod offers NovoBody, LuxSit™ Pro, and NovoLISA.
Monod has 8 investors. Key investors include HHS, Matrix Capital, Pack Ventures, Sahsen Ventures, and BOOM Capital.